FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367842017> ?p ?o ?g. }

• W4367842017 endingPage "1269" @default.
• W4367842017 startingPage "1260" @default.
• W4367842017 abstract "Background Since 2015, Dutch guidelines have recommended BRCA1/2 pathogenic variant testing for all patients with epithelial ovarian cancer. Recently, recommendations shifted from germline testing to the tumor-first approach, in which tumor tissue is tested first, and subsequent germline testing is performed only in those with BRCA1/2 tumor pathogenic variants or a positive family history. Data on testing rates and on characteristics of patients missing out on testing remain scarce. Objective To evaluate BRCA1/2 testing rates in patients with epithelial ovarian cancer and compare testing rates of germline testing (performed from 2015 until mid-2018) versus tumor-first testing (implemented mid-2018). Methods A consecutive series of 250 patients diagnosed with epithelial ovarian cancer between 2016 and 2019 was included from the OncoLifeS data-biobank of the University Medical Center Groningen, the Netherlands. Testing rates were analyzed for the overall study population and for germline testing (period I) and tumor-first testing (period II) separately. Characteristics of tested and untested patients were compared and predictors for receiving testing were assessed with multivariable logistic regression. Results Median age was 67.0 years (IQR 59.0–73.0) and 173 (69.2%) patients were diagnosed with high-grade serous carcinoma. Overall, 201 (80.4%) patients were tested. In period I, 137/171 (80.1%) patients were tested and in period II this was 64/79 (81.0%). Patients with non-high-grade serous carcinoma were significantly less likely to receive BRCA1/2 testing than patients with high-grade serous carcinoma (OR=0.23, 95% CI 0.11 to 0.46, p<0.001). Conclusions The results show that BRCA1/2 testing rates are suboptimal and suggest that clinicians may not be choosing to test patients with epithelial ovarian cancer with non-high-grade serous ovarian carcinoma, although guidelines recommend BRCA1/2 testing in all patients with epithelial ovarian cancer. Suboptimal testing rates limit optimization of care for patients with epithelial ovarian cancer and counseling of potentially affected relatives." @default.
• W4367842017 created "2023-05-04" @default.
• W4367842017 creator A5000314896 @default.
• W4367842017 creator A5003474947 @default.
• W4367842017 creator A5035436147 @default.
• W4367842017 creator A5043337594 @default.
• W4367842017 creator A5050915012 @default.
• W4367842017 creator A5058698695 @default.
• W4367842017 creator A5060341723 @default.
• W4367842017 creator A5085674384 @default.
• W4367842017 date "2023-05-03" @default.
• W4367842017 modified "2023-09-25" @default.
• W4367842017 title "<i>BRCA1/2</i>testing rates in epithelial ovarian cancer: a focus on the untested patients" @default.
• W4367842017 cites W1977651703 @default.
• W4367842017 cites W2117177285 @default.
• W4367842017 cites W2135525536 @default.
• W4367842017 cites W2169983032 @default.
• W4367842017 cites W2745994405 @default.
• W4367842017 cites W2752362337 @default.
• W4367842017 cites W2800059249 @default.
• W4367842017 cites W2901855294 @default.
• W4367842017 cites W2938370698 @default.
• W4367842017 cites W2944695242 @default.
• W4367842017 cites W2947815207 @default.
• W4367842017 cites W2987621554 @default.
• W4367842017 cites W3160293272 @default.
• W4367842017 cites W3210059904 @default.
• W4367842017 doi "https://doi.org/10.1136/ijgc-2023-004307" @default.
• W4367842017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37137525" @default.
• W4367842017 hasPublicationYear "2023" @default.
• W4367842017 type Work @default.
• W4367842017 citedByCount "0" @default.
• W4367842017 crossrefType "journal-article" @default.
• W4367842017 hasAuthorship W4367842017A5000314896 @default.
• W4367842017 hasAuthorship W4367842017A5003474947 @default.
• W4367842017 hasAuthorship W4367842017A5035436147 @default.
• W4367842017 hasAuthorship W4367842017A5043337594 @default.
• W4367842017 hasAuthorship W4367842017A5050915012 @default.
• W4367842017 hasAuthorship W4367842017A5058698695 @default.
• W4367842017 hasAuthorship W4367842017A5060341723 @default.
• W4367842017 hasAuthorship W4367842017A5085674384 @default.
• W4367842017 hasBestOaLocation W43678420171 @default.
• W4367842017 hasConcept C104317684 @default.
• W4367842017 hasConcept C109825262 @default.
• W4367842017 hasConcept C121608353 @default.
• W4367842017 hasConcept C126322002 @default.
• W4367842017 hasConcept C143998085 @default.
• W4367842017 hasConcept C150173356 @default.
• W4367842017 hasConcept C151956035 @default.
• W4367842017 hasConcept C185592680 @default.
• W4367842017 hasConcept C2777632260 @default.
• W4367842017 hasConcept C2780427987 @default.
• W4367842017 hasConcept C2780673598 @default.
• W4367842017 hasConcept C2908647359 @default.
• W4367842017 hasConcept C29456083 @default.
• W4367842017 hasConcept C3019054536 @default.
• W4367842017 hasConcept C55493867 @default.
• W4367842017 hasConcept C71924100 @default.
• W4367842017 hasConcept C99454951 @default.
• W4367842017 hasConceptScore W4367842017C104317684 @default.
• W4367842017 hasConceptScore W4367842017C109825262 @default.
• W4367842017 hasConceptScore W4367842017C121608353 @default.
• W4367842017 hasConceptScore W4367842017C126322002 @default.
• W4367842017 hasConceptScore W4367842017C143998085 @default.
• W4367842017 hasConceptScore W4367842017C150173356 @default.
• W4367842017 hasConceptScore W4367842017C151956035 @default.
• W4367842017 hasConceptScore W4367842017C185592680 @default.
• W4367842017 hasConceptScore W4367842017C2777632260 @default.
• W4367842017 hasConceptScore W4367842017C2780427987 @default.
• W4367842017 hasConceptScore W4367842017C2780673598 @default.
• W4367842017 hasConceptScore W4367842017C2908647359 @default.
• W4367842017 hasConceptScore W4367842017C29456083 @default.
• W4367842017 hasConceptScore W4367842017C3019054536 @default.
• W4367842017 hasConceptScore W4367842017C55493867 @default.
• W4367842017 hasConceptScore W4367842017C71924100 @default.
• W4367842017 hasConceptScore W4367842017C99454951 @default.
• W4367842017 hasFunder F4320307770 @default.
• W4367842017 hasIssue "8" @default.
• W4367842017 hasLocation W43678420171 @default.
• W4367842017 hasLocation W43678420172 @default.
• W4367842017 hasOpenAccess W4367842017 @default.
• W4367842017 hasPrimaryLocation W43678420171 @default.
• W4367842017 hasRelatedWork W2004144597 @default.
• W4367842017 hasRelatedWork W2019814960 @default.
• W4367842017 hasRelatedWork W2116186978 @default.
• W4367842017 hasRelatedWork W2398330439 @default.
• W4367842017 hasRelatedWork W2805900528 @default.
• W4367842017 hasRelatedWork W2954396991 @default.
• W4367842017 hasRelatedWork W3210326642 @default.
• W4367842017 hasRelatedWork W4243197346 @default.
• W4367842017 hasRelatedWork W4327675405 @default.
• W4367842017 hasRelatedWork W4385380379 @default.
• W4367842017 hasVolume "33" @default.
• W4367842017 isParatext "false" @default.
• W4367842017 isRetracted "false" @default.
• W4367842017 workType "article" @default.